Sean McCutcheon
Stock Analyst at Raymond James
(2.13)
# 1,505
Out of 5,090 analysts
11
Total ratings
36.36%
Success rate
3.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean McCutcheon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Strong Buy | $72 → $76 | $79.64 | -4.57% | 2 | Oct 17, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $6.50 | +84.62% | 1 | Jul 11, 2025 | |
| JANX Janux Therapeutics | Initiates: Outperform | $65 | $16.51 | +293.70% | 1 | Jul 11, 2025 | |
| CMPX Compass Therapeutics | Reinstates: Outperform | $9 | $5.53 | +62.75% | 1 | Jul 1, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Outperform | $11 | $2.67 | +311.99% | 1 | Jul 1, 2025 | |
| ENGN enGene Holdings | Initiates: Outperform | $23 | $8.07 | +185.01% | 1 | Nov 27, 2024 | |
| XNCR Xencor | Maintains: Strong Buy | $58 → $40 | $17.30 | +131.21% | 1 | Jun 14, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $92 → $70 | $65.67 | +6.59% | 2 | May 23, 2024 | |
| LEGN Legend Biotech | Initiates: Outperform | $86 | $28.13 | +205.72% | 1 | Mar 13, 2024 |
Revolution Medicines
Oct 17, 2025
Maintains: Strong Buy
Price Target: $72 → $76
Current: $79.64
Upside: -4.57%
Vir Biotechnology
Jul 11, 2025
Initiates: Outperform
Price Target: $12
Current: $6.50
Upside: +84.62%
Janux Therapeutics
Jul 11, 2025
Initiates: Outperform
Price Target: $65
Current: $16.51
Upside: +293.70%
Compass Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $9
Current: $5.53
Upside: +62.75%
Black Diamond Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $11
Current: $2.67
Upside: +311.99%
enGene Holdings
Nov 27, 2024
Initiates: Outperform
Price Target: $23
Current: $8.07
Upside: +185.01%
Xencor
Jun 14, 2024
Maintains: Strong Buy
Price Target: $58 → $40
Current: $17.30
Upside: +131.21%
Cytokinetics
May 23, 2024
Maintains: Outperform
Price Target: $92 → $70
Current: $65.67
Upside: +6.59%
Legend Biotech
Mar 13, 2024
Initiates: Outperform
Price Target: $86
Current: $28.13
Upside: +205.72%